Plain-English translation of NCT07245992 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called that is injected directly into inflamed joints in people with rheumatoid arthritis. Researchers want to find the right dose of this treatment and learn if it is safe and effective for reducing joint inflammation when standard medications alone are not controlling symptoms well enough.
Many people with rheumatoid arthritis continue to have flare-ups in specific joints even while taking their regular medications. This trial exists to see if this new medication, injected directly into problem joints, could offer an additional treatment option to help control these stubborn joint flares.
You likely qualify if…
You likely don't qualify if…
You would receive three injections of the medication directly into one of your inflamed joints, spaced 4 weeks apart. The trial starts by testing low doses in small groups and gradually increases the dose as safety is confirmed. After your injections are complete, you would return for follow-up visits for up to 6 months to monitor how well the treatment works and watch for any side effects. The entire study commitment is approximately 9 months.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Italy
Phase
Safety & dosing
Sponsor
Philogen S.p.A.
Enrollment target
~42 participants
Started
January 2026
Primary completion
September 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Louis Plüss
Philogen S.p.A.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.